ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

In Brief: NCHSR Says Autologous Marrow Transplant Is A “Reasonable Therapeutic Alternative”

August 11, 1989

In Brief: Metcalf, Sachs, Nowell, Rowley, Elkind Win 1989 GM Award; Ray Morrison Retires

June 16, 1989

New Concepts Being Developed By Organ Systems Groups Described

January 2, 1987

Cancer Prevention: Review Group’s Report Urges Integration Of Prevention with all NCI Research

June 27, 1997

Clolar Approved for Pediatric Refractory/Relapsed ALL

January 28, 2005

DCPC Plans Future RFAs, But Most Will Depend n bypass Budget

June 22, 1990